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7 RCTs), local (HR=0.79 0.67-0.94, p=0.0075, 7 RCTs) and distant 
recurrence-free interval (HR=0.75, 0.66-0.87, p<0.0001, 7 RCTs). 
In both comparisons the results of older and more recent RCTs were 
comparable. There was no clear evidence of a difference in effect of 
CT by type of CT, nor that any patient subgroup deﬁned by age, sex or 
histology beneﬁted more or less from CT. There was a suggestion of a 
trend in effect of CT by stage for comparison 1 (p=0.047).
Conclusion: Results from 41 RCTs and over 10,000 patients demon-
strate conclusively a beneﬁt of adjuvant CT in NSCLC, both in pres-
ence or absence of adjuvant radiotherapy. These results are consistent 
irrespective of the regimen used, the patient subgroup treated or the 
endpoint assessed, thus providing reliable estimates on which to base 
future policies and research.
Comparison 1: supported by the UK Medical Research Council
Comparison 3: Unrestricted grants from French PHRC, LNCC and 
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Background: Non-small cell lung cancer patients with excision repair 
cross-complementation group 1 (ERCC1) overexpression have lower 
response to cisplatin-based chemotherapy. Preliminary study also 
suggests that ERCC1 expression was associated with radioresistant 
in the lung cancer cells. Objective: Aim of our study was to evaluate 
the predictive value of ERCC1 expression in Stage IIIA, N2 positive 
non-small cell lung cancer (NSCLC) patients treated with neoadjuvant 
concurrent chemoradiotherapy (CCRT) followed by surgery.
Method: Seventy-one patients were enrolled between August 1997 and 
September 2003. We analyzed ERCC1 protein expression from 71 pa-
tients who underwent mediastinoscopic biopsy and proven N2 disease 
before CCRT by immunohistochemistry. All patients were treated with 
neoadjuvant CCRT followed by surgery . We evaluated the correlation 
of ERCC1 expression with various clinicopathological factors, includ-
ing overall survival. 
Result: Among 71 specimens, ERCC1 expression was positive in 32 
(45.1%) and negative in 39 (54.9%) patients. At a median follow-up 
of 32.5 months (range: 3.8-99.5), the median disease-free and overall 
survival were 26.4 months (95% CI: 12.1-40.8) and 42.6 months (95% 
CI: 23.9-61.3), respectively in all patients. ERCC1-negative group, as 
compared with ERCC1-positive group, showed signiﬁcantly prolonged 
disease free survival (DFS: 34.0 vs 15.8 months, p=0.014) and overall 
survival (OS: 65.1 vs 20.5 months, p=0.001). In multivariate analy-
ses negative ERCC1 expression (p=0.001), age < 55 yrs at diagnosis 
(p=0.002) and achieving downstage after CCRT (p=0.003) were statis-
tically signiﬁcant independent good prognostic factors for survival. 
Conclusion: These results suggested that stage IIIA, N2 positive 
NSCLC patients with ERCC1-negative tumors showed survival beneﬁt 
from CCRT with cisplatin-containing regimen and ERCC1 expression 
would be a useful for predictive and prognostic marker. 
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Background: Outcome of patients (pts) with locally advanced NSCLC 
treated with radiotherapy- or chemoradiotherapy is poor. Tumor recur-
rence is observed both locally and distant metastatic sites. Advances 
in surgery allow considering resection in selected patients with locally 
advanced tumor stages, in particular after prior neoadjuvant therapy 
and tumor downstaging. Little prospective data are available on the 
feasibility, associated toxicity and outcome of such an approach. 
Treatment and Methods: This phase II trial aims at evaluating fea-
sibility and outcome of a tri-modality concept of neoadjuvant chemo-
therapy, radiotherapy (RT) followed by deﬁnitive surgery in operable, 
stage IIIB NSCLC pts. Primary endpoint is progression- and relapse-
free survival at 1 year. Treatment consisted of 3 cycles of cisplatin (100 
mg/m2) and docetaxel (85 mg/m2) followed by accelerated, concomitant 
boost RT (44 Gy/22 fx over 3 weeks) and surgery. Operable pts up to 
age 75 and a performance status of 0-1 with stage IIIB NSCLC (pleural 
effusion excluded) were eligible. 
Results: Forty-ﬁve eligible pts (46 accrued) with a median age was 
60 years (range 28-70) were treated between September 2001 and 
May 2006. All patients were staged with PET and/or mediastinoscopy. 
Tumor localization was right-sided in 28 pts and left-sided in 17 pts. 
Histology was squamous cell 42%, large cell 11%, adeno-13% and 
undifferentiated carcinoma 33%. N3-disease was present in 29%, T4 
stage in 78%. Chemotherapy (45 pts) administered as prescribed in 
>80% of cycles. Thirty-six pts (80%) received RT as planned, RT was 
omitted in 6 patients due to early progression, and in 3 patients due to 
complications during the chemotherapy. The objective response rate 
after chemotherapy was 53% (95% c.i. 38-68%), after additional RT 
67% (51-80%). 
Thirty-one pts (69%) underwent surgery, the median time from enroll-
ment to surgery was 3.7 months (2.8 - 5.2). Seventeen patients under-
went pneumonectomy, in the other patients bilobectomy or lobectomy 
was performed. A complete (R0) resection was achieved in 24 pts 
(75% of operated patients, 56% of all pts). Perioperative complications 
occurred in 13 pts, including 2 pts dying from ARDS and a cerebro-
vascular event, respectively. Seven pts required a second surgical 
intervention. The median duration of surgical hospitalization was 12 
days (8-134). 
